NEUROENDOCRINE CARCINOMA OF PROSTATE

This adverse event was reported 18 times

These drugs are most commonly taken by patients reporting NEUROENDOCRINE CARCINOMA OF PROSTATE:

# Drug Count
0 LEUPROLIDE ACETATE 4
1 DOCETAXEL 3
2 DOCETAXEL ANHYDROUS 3
3 BICALUTAMIDE 2
4 CARBOPLATIN 2
5 ENZALUTAMIDE 2
6 ABIRATERONE ACETATE 1
7 ALISKIREN 1
8 ALISKIREN HEMIFUMARATE 1
9 AMLODIPINE 1
See all common drugs associated with NEUROENDOCRINE CARCINOMA OF PROSTATE

NEUROENDOCRINE CARCINOMA OF PROSTATE is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LAROTRECTINIB 1 0.0025
1 CABAZITAXEL 1 0.0004
2 ALISKIREN HEMIFUMARATE 1 0.0002
3 BICALUTAMIDE 2 0.0002
4 TERAZOSIN HYDROCHLORIDE 1 0.0001
5 EVEROLIMUS TABLETS 1 0.0001
6 LEUPROLIDE ACETATE 4 0.0001
7 DOCETAXEL ANHYDROUS 3 0.0001
8 ENZALUTAMIDE 2 0.0000
9 ABIRATERONE ACETATE 1 0.0000
See all drugs enriched for association with NEUROENDOCRINE CARCINOMA OF PROSTATE

NEUROENDOCRINE CARCINOMA OF PROSTATE is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Androgen Receptor Inhibitor [EPC] 4 0.0001
1 Microtubule Inhibitor [EPC] 4 0.0000
2 Topoisomerase Inhibitor [EPC] 1 0.0000
3 Platinum-based Drug [EPC] 3 0.0000
4 Interleukin-12 Antagonist [EPC] 1 0.0000
5 Interleukin-23 Antagonist [EPC] 1 0.0000
6 Aldosterone Antagonist [EPC] 1 0.0000
7 alpha-Adrenergic Blocker [EPC] 1 0.0000
8 Osmotic Laxative [EPC] 1 0.0000
9 Kinase Inhibitor [EPC] 2 0.0000
See all drug classes enriched for association with NEUROENDOCRINE CARCINOMA OF PROSTATE